Analyst firms · Leerink Partners · AXSM
Leerink Partners AXSM price target and rating history
Axsome Therapeutics Inc. (AXSM) · Health Care
Leerink Partners rates Axsome Therapeutics Inc. (AXSM) Outperform with a $50 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on AXSM since August 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50.
- Current rating
- Outperform
- Price target
- $50
- Median target, all firms
- $257.50
- Actions on AXSM
- 3
Leerink Partners price target on AXSM
Every Leerink Partners rating on AXSM
- Mar 2, 2022
- Nov 9, 2021
- Aug 10, 2021
How other firms rate AXSM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Buy | $285 | Sep 23, 2026 |
| BMO Capital Markets | Outperform | $310 | Jul 21, 2026 |
| Wolfe Research | Outperform | $230 | Feb 24, 2026 |
| Morgan Stanley | Equal-Weight | $204 | Jan 8, 2026 |
Questions about Leerink Partners and AXSM
- What is Leerink Partners's price target for AXSM?
- Leerink Partners's latest stated price target for Axsome Therapeutics Inc. (AXSM) is $50, from its action on Mar 2, 2022.
- What is Leerink Partners's rating on AXSM?
- Leerink Partners rates AXSM Outperform, a bullish rating, as of Mar 2, 2022.
- When did Leerink Partners last change its view on AXSM?
- On Mar 2, 2022, Leerink Partners cuts its price target to $50 from $65, keeps Outperform.
- How does Leerink Partners's AXSM target compare with other analysts?
- Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50.
More AXSM rating histories
All Leerink Partners ratingsAXSM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.